These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M; Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954 [TBL] [Abstract][Full Text] [Related]
4. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354 [TBL] [Abstract][Full Text] [Related]
5. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344 [TBL] [Abstract][Full Text] [Related]
6. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation. Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769 [TBL] [Abstract][Full Text] [Related]
7. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients. Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744 [TBL] [Abstract][Full Text] [Related]
8. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients. Reischig T; Nemcová J; Vanecek T; Jindra P; Hes O; Bouda M; Treska V Antivir Ther; 2010; 15(1):23-30. PubMed ID: 20167988 [TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation. Lapidus-Krol E; Shapiro R; Amir J; Davidovits M; Steinberg R; Mor E; Avitzur Y Pediatr Transplant; 2010 Sep; 14(6):753-60. PubMed ID: 20477976 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients. Luan FL; Chopra P; Park J; Norman S; Cibrik D; Ojo A Transplant Proc; 2006 Dec; 38(10):3673-5. PubMed ID: 17175363 [TBL] [Abstract][Full Text] [Related]
11. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. van der Beek MT; Berger SP; Vossen AC; van der Blij-de Brouwer CS; Press RR; de Fijter JW; Claas EC; Kroes AC Transplantation; 2010 Feb; 89(3):320-6. PubMed ID: 20145523 [TBL] [Abstract][Full Text] [Related]
12. Initial experience with oral valganciclovir for pre-emptive cytomegalovirus therapy after lung transplantation. Aigner C; Jaksch P; Winkler G; Czebe K; Taghavi S; Marta G; Klepetko W Wien Klin Wochenschr; 2005 Jul; 117(13-14):480-4. PubMed ID: 16091875 [TBL] [Abstract][Full Text] [Related]